Cargando…

Validation of Next Generation Sequencing Technologies in Comparison to Current Diagnostic Gold Standards for BRAF, EGFR and KRAS Mutational Analysis

Next Generation Sequencing (NGS) has the potential of becoming an important tool in clinical diagnosis and therapeutic decision-making in oncology owing to its enhanced sensitivity in DNA mutation detection, fast-turnaround of samples in comparison to current gold standard methods and the potential...

Descripción completa

Detalles Bibliográficos
Autores principales:	McCourt, Clare M., McArt, Darragh G., Mills, Ken, Catherwood, Mark A., Maxwell, Perry, Waugh, David J., Hamilton, Peter, O'Sullivan, Joe M., Salto-Tellez, Manuel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3724913/ https://www.ncbi.nlm.nih.gov/pubmed/23922754 http://dx.doi.org/10.1371/journal.pone.0069604

Ejemplares similares

Translation of tissue-based artificial intelligence into clinical practice: from discovery to adoption
por: Geaney, Alice, et al.
Publicado: (2023)

cudaMap: a GPU accelerated program for gene expression connectivity mapping
por: McArt, Darragh G, et al.
Publicado: (2013)

Epidermal growth factor receptor immunohistochemistry: new opportunities in metastatic colorectal cancer
por: Hutchinson, Ryan A, et al.
Publicado: (2015)

Quantification of HER2 heterogeneity in breast cancer–implications for identification of sub-dominant clones for personalised treatment
por: Buckley, Niamh E., et al.
Publicado: (2016)

Molecular classification of non-invasive breast lesions for personalised therapy and chemoprevention
por: Buckley, Niamh, et al.
Publicado: (2015)

Connectivity Mapping for Candidate Therapeutics Identification Using Next Generation Sequencing RNA-Seq Data
por: McArt, Darragh G., et al.
Publicado: (2013)

Embracing an integromic approach to tissue biomarker research in cancer: Perspectives and lessons learned
por: Li, Gerald, et al.
Publicado: (2017)

KRAS mutant colorectal cancer gene signatures identified angiotensin II receptor blockers as potential therapies
por: Wen, Qing, et al.
Publicado: (2016)

EGFR, PIK3CA, KRAS and BRAF mutations in meningiomas
por: BUJKO, MATEUSZ, et al.
Publicado: (2014)

Prostate cancer heterogeneity assessment with multi-regional sampling and alignment-free methods
por: Murphy, Ross G, et al.
Publicado: (2020)

Identification of Candidate Small-Molecule Therapeutics to Cancer by Gene-Signature Perturbation in Connectivity Mapping
por: McArt, Darragh G., et al.
Publicado: (2011)

Automated tumor analysis for molecular profiling in lung cancer
por: Hamilton, Peter W., et al.
Publicado: (2015)

Evaluation of EGFR, KRAS and BRAF gene mutations in renal cell carcinoma
por: Bayrak, Omer, et al.
Publicado: (2014)

EGFR Expression and KRAS and BRAF Mutational Status in Intestinal-Type Sinonasal Adenocarcinoma
por: Szablewski, Vanessa, et al.
Publicado: (2013)

Stratified analysis reveals chemokine-like factor (CKLF) as a potential prognostic marker in the MSI-immune consensus molecular subtype CMS1 of colorectal cancer
por: Dunne, Philip D., et al.
Publicado: (2016)

Delivering a research‐enabled multistakeholder partnership for enhanced patient care at a population level: The Northern Ireland Comprehensive Cancer Program
por: Lawler, Mark, et al.
Publicado: (2015)

Influence of Vitamin D Status and Supplementation on Metabolomic Profiles of Older Adults
por: McCourt, Aislinn F., et al.
Publicado: (2023)

High frequency of KRAS and EGFR mutation profiles in BRAF-negative thyroid carcinomas in Indonesia
por: Heriyanto, Didik Setyo, et al.
Publicado: (2022)

Transcriptional Profiling of a Patient-Matched Cohort of Glioblastoma (IDH-Wildtype) for Therapeutic Target and Repurposing Drug Identification
por: Roddy, Aideen C., et al.
Publicado: (2023)

NUQA: Estimating Cancer Spatial and Temporal Heterogeneity and Evolution through Alignment-Free Methods
por: Roddy, Aideen C, et al.
Publicado: (2019)

Pyrosequencing data analysis software: a useful tool for EGFR, KRAS, and BRAF mutation analysis
por: Shen, Shanxiang, et al.
Publicado: (2012)

Comprehensive molecular pathology analysis of small bowel adenocarcinoma reveals novel targets with potential for clinical utility
por: Alvi, Muhammad A., et al.
Publicado: (2015)

QuPath: Open source software for digital pathology image analysis
por: Bankhead, Peter, et al.
Publicado: (2017)

Concordance of KRAS/BRAF Mutation Status in Metastatic Colorectal Cancer before and after Anti-EGFR Therapy
por: Gattenlöhner, S., et al.
Publicado: (2009)

EGFR, KRAS, BRAF, and HER-2 molecular status in brain metastases from 77 NSCLC patients
por: Villalva, Claire, et al.
Publicado: (2013)

EGFR, ALK, RET, KRAS and BRAF alterations in never-smokers with non-small cell lung cancer
por: DONG, YU, et al.
Publicado: (2016)

EGFR, KRAS, BRAF, ALK, and cMET genetic alterations in 1440 Sardinian patients with lung adenocarcinoma
por: Colombino, Maria, et al.
Publicado: (2019)

QUADrATiC: scalable gene expression connectivity mapping for repurposing FDA-approved therapeutics
por: O’Reilly, Paul G., et al.
Publicado: (2016)

Clinical pharmacogenomic testing of KRAS, BRAF and EGFR mutations by high resolution melting analysis and ultra-deep pyrosequencing
por: Borràs, Emma, et al.
Publicado: (2011)

Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma: Occurence and prognostic significance
por: Módos, Orsolya, et al.
Publicado: (2016)

EGFR, KRAS, BRAF, PTEN, and PIK3CA mutation in plasma of small cell lung cancer patients
por: Lu, Hong-Yang, et al.
Publicado: (2018)

Evaluation on the Distribution of EGFR, KRAS and BRAF Genes and the Expression of PD-L1 in Different Types of Lung Cancer
por: Zhao, Rui, et al.
Publicado: (2021)

KRAS and BRAF genotyping of synchronous colorectal carcinomas
por: GIANNINI, RICCARDO, et al.
Publicado: (2014)

A gene signature associated with PTEN activation defines good prognosis intermediate risk prostate cancer cases
por: Ong, Chee W, et al.
Publicado: (2018)

Novel deep learning-based solution for identification of prognostic subgroups in liver cancer (Hepatocellular carcinoma)
por: Owens, Alice R., et al.
Publicado: (2021)

Significant Improvement in Detecting BRAF, KRAS, and EGFR Mutations Using Next-Generation Sequencing as Compared with FDA-Cleared Kits
por: Ma, Wanlong, et al.
Publicado: (2017)

Construction of a reference material panel for detecting KRAS/NRAS/EGFR/BRAF/MET mutations in plasma ctDNA
por: Xu, Jun, et al.
Publicado: (2021)

The prognostic value of the stem-like group in colorectal cancer using a panel of immunohistochemistry markers
por: Ong, Chee Wee, et al.
Publicado: (2015)

Robustness of differential gene expression analysis of RNA-seq
por: Stupnikov, A., et al.
Publicado: (2021)

Evolutionary genetic algorithm identifies IL2RB as a potential predictive biomarker for immune-checkpoint therapy in colorectal cancer
por: Alderdice, Matthew, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dobj08odh8iainbn9vv54b0k6t